Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center

The Journal of Clinical Psychiatry
K Ryan ConnollyJohn P O'Reardon

Abstract

Transcranial magnetic stimulation (TMS) is a US Food and Drug Administration-approved treatment for major depressive disorder (MDD) in patients who have not responded to 1 adequate antidepressant trial in the current episode. In a retrospective cohort study, we examined the effectiveness and safety of TMS in the first 100 consecutive patients treated for depression (full DSM-IV criteria for major depressive episode in either major depressive disorder or bipolar disorder) at an academic medical center between July 21, 2008, and March 25, 2011. TMS was flexibly dosed in a course of up to 30 sessions, adjunctive to current medications, for 85 patients treated for acute depression. The primary outcomes were response and remission rates at treatment end point as measured by the Clinical Global Impressions-Improvement scale (CGI-I) at 6 weeks. Secondary outcomes included change in the Hamilton Depression Rating Scale (HDRS); Quick Inventory of Depressive Symptomatology, self-report (QIDS-SR); Beck Depression Inventory (BDI); Beck Anxiety Inventory (BAI); and the Sheehan Disability Scale (SDS). Enduring benefit was assessed over 6 months in patients receiving maintenance TMS treatment. Data from 12 patients who received TMS as mainten...Continue Reading

Citations

Oct 12, 2012·Current Psychiatry Reports·Mayur PandyaAmit Anand
May 29, 2013·Current Psychiatry Reports·Daniel M BlumbergerZafiris J Daskalakis
Jul 23, 2014·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Marcelo T BerlimGustavo Turecki
Jul 3, 2013·Journal of Affective Disorders·Gretchen J DiefenbachJohn W Goethe
Jun 25, 2013·Journal of Affective Disorders·Raphaëlle RichieriLaurent Boyer
May 28, 2013·Journal of Affective Disorders·Nora Weiduschat, Marc J Dubin
Mar 1, 2014·Revista colombiana de psiquiatría·Mayra MalaveraSandra Carrillo
Oct 30, 2016·Journal of Affective Disorders·Stephan F TaylorJesse Wright
Nov 4, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Frédéric HaesebaertEmmanuel Poulet
Jun 29, 2017·The New England Journal of Medicine·Andre R BrunoniUNKNOWN ELECT-TDCS Investigators
Aug 4, 2016·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Roumen V MilevUNKNOWN CANMAT Depression Work Group
Oct 1, 2019·Brain and Behavior·Alexandra K GoldGustavo Kinrys
Mar 29, 2018·Translational Neurodegeneration·Alexandra M LesenskyjChristina R Maxwell
Apr 30, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Anna LatorreJohn C Rothwell
Aug 14, 2020·Translational Psychiatry·M Moreno-OrtegaD C Javitt
May 12, 2017·Neural Plasticity·Yu-Jhen HuangChieh-Hsin Lin
Oct 5, 2019·The American Journal of Psychiatry·Andrea L CrowellHelen S Mayberg
Apr 2, 2019·International Journal of Psychiatry in Clinical Practice·Chris GriffithsKsenija da Silva
Mar 27, 2020·Frontiers in Systems Neuroscience·Robert D Black, Lesco L Rogers
Nov 17, 2012·Current Opinion in Psychiatry·Mark S GeorgeE Baron Short
Nov 11, 2020·Brain and Behavior·Eric L GoldwaserScott T Aaronson
Sep 17, 2020·Journal of Psychiatric Practice·Michael J Minzenberg, Jong H Yoon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.